Opthalmology Times, Digital Edition, March 1st, 2011

Related Videos
Related Content

BREAKING NEWS: FDA approves Novaliq’s cyclosporine ophthalmic solution for treatment of dry eye disease

June 8th 2023

Podcast: Wet AMD and the treatment burden on patients

May 3rd 2023

OKYO Pharma announces dosing of first patient in randomized portion of phase 2 trial of OK-101

June 8th 2023

Podcast: AI/MR in ophthalmology: The future is now

April 7th 2023

Joey Gase named ambassador by National Keratoconus Foundation

June 6th 2023

Vyluma announces FDA acceptance of NDA for NVK002 for treatment of pediatric myopia

June 6th 2023

BREAKING NEWS: FDA approves Novaliq’s cyclosporine ophthalmic solution for treatment of dry eye disease

June 8th 2023

Podcast: Wet AMD and the treatment burden on patients

May 3rd 2023

OKYO Pharma announces dosing of first patient in randomized portion of phase 2 trial of OK-101

June 8th 2023

Podcast: AI/MR in ophthalmology: The future is now

April 7th 2023

Joey Gase named ambassador by National Keratoconus Foundation

June 6th 2023

Vyluma announces FDA acceptance of NDA for NVK002 for treatment of pediatric myopia

June 6th 2023

BREAKING NEWS: FDA approves Novaliq’s cyclosporine ophthalmic solution for treatment of dry eye disease

June 8th 2023

Podcast: Wet AMD and the treatment burden on patients

May 3rd 2023

OKYO Pharma announces dosing of first patient in randomized portion of phase 2 trial of OK-101

June 8th 2023

Podcast: AI/MR in ophthalmology: The future is now

April 7th 2023

Joey Gase named ambassador by National Keratoconus Foundation

June 6th 2023

Vyluma announces FDA acceptance of NDA for NVK002 for treatment of pediatric myopia

June 6th 2023
© 2023 MJH Life Sciences

All rights reserved.